Scilex Holding (SCLX) Other Operating Expenses (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Other Operating Expenses of -$18.1 million for Q1 2026, down 7.0% on a QoQ basis from -$16.9 million in Q4 2025.
Scilex Holding (SCLX) Other Operating Expenses (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Other Operating Expenses for 7 consecutive years, with -$18.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses changed N/A year-over-year to -$18.1 million; the TTM figure through Mar 2026 stood at -$25.9 million (down 579.86% YoY), while the FY2025 annual figure was -$12.2 million, changed N/A from the prior year.
- Other Operating Expenses came in at -$18.1 million for Q1 2026 at Scilex Holding, down from -$16.9 million in the prior quarter.
- The five-year high for Other Operating Expenses was $5.5 million in Q4 2023, with the low at -$18.1 million in Q1 2026.
- Average Other Operating Expenses over 5 years is $418558.1, with a median of $4.4 million recorded in 2023.
- Across the five-year window, Other Operating Expenses jumped 4961.73% in 2022 and plunged 143.83% in 2024, its largest moves.
- Year by year, Other Operating Expenses stood at $5.5 million in 2022, then gained by 0.14% to $5.5 million in 2023, then dropped by 2.81% to $5.4 million in 2024, then tumbled by 413.15% to -$16.9 million in 2025, then fell by 7.0% to -$18.1 million in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered -$18.1 million, -$16.9 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.06 Mn |
| Dec 31, 2025 | -16.88 Mn |
| Sep 30, 2025 | 4.70 Mn |
| Jun 30, 2025 | 4.38 Mn |
| Jun 30, 2024 | 5.39 Mn |
| Mar 31, 2024 | -2.02 Mn |
| Dec 31, 2023 | 5.55 Mn |
| Sep 30, 2023 | 4.42 Mn |
| Jun 30, 2023 | 5.20 Mn |
| Mar 31, 2023 | 4.62 Mn |
| Dec 31, 2022 | 5.54 Mn |
| Sep 30, 2022 | 526,359.00 |
| Jun 30, 2022 | 3.00 Mn |
| Mar 31, 2022 | -485,807.00 |
| Dec 31, 2021 | 1.52 Mn |
| Sep 30, 2021 | -1.16 Mn |
| Jun 30, 2021 | -61,609.00 |
| Mar 31, 2021 | 1.49 Mn |
| Dec 31, 2020 | 6,276.00 |
| Sep 30, 2020 | 856.00 |